Abstract:Trung N Tran, 1 Heath Heatley, 2 Arnaud Bourdin, 3 Andrew Menzies-Gow, 4, 5 David J Jackson, 6 Ekaterina Maslova, 5 Jatin Chapaneri, 5 William Henley, 2, 7 Victoria Carter, 2 Jeffrey Shi Kai Chan, 2 Cono Ariti, 2 John Haughney, 8, 9 David Price 2, 9 1 BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA; 2 Observational and Pragmatic Research Institute, Singapore; 3 Department of Respiratory Diseases, PhyMedExp, University of Montpellier, Montpellier, France; 4 Royal Brompton & Harefield Hospitals and School of Immunology & Microbial Sciences, King's College London, London, UK; 5 BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK; 6 Guy's Severe Asthma Centre, Guy's and St Thomas' Hospitals, School of Immunology & Microbial Sciences, King's College London, London, UK; 7 Department of Health and Community Sciences University of Exeter Medical School, Exeter, UK; 8 NHS Clinical Research Facilities, Glasgow, UK; 9 Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK Correspondence: David Price, Observational and Pragmatic Research Institute, 22 Sin Ming Lane, &num06-76, Midview City, 573969, Singapore, Tel +65 3105 1489, Email Purpose: Oral corticosteroid (OCS) use for asthma is associated with considerable healthcare resource utilization (HCRU) and costs. However, no study has investigated this in relation to patterns of intermittent OCS prescription. Methods: This historical UK cohort study used primary care medical records, linked to Hospital Episode Statistics, from 2008 to 2019, of patients (≥ 4 years old) with asthma prescribed intermittent OCS. Patients were categorized by OCS prescribing pattern (one-off [single], less frequent [≥ 90-day gap] and frequent [< 90-day gap]) and matched 1:1 (by sex, age and index date) with people never prescribed OCS with/without asthma. HCRU (reported as episodes, except for length of hospital stay [days] and any prescription [records]) and associated costs were compared between intermittent OCS and non-OCS cohorts, and among intermittent OCS prescribing patterns. Results: Of 149,191 eligible patients, 50.3% had one-off, 27.4% less frequent, and 22.3% frequent intermittent OCS prescribing patterns. Annualized non-respiratory HCRU rates were greater in the intermittent OCS versus non-OCS cohorts for GP visits (5.93 vs 4.70 episodes, p < 0.0001), hospital admissions (0.24 vs 0.16 episodes, p < 0.0001), and length of stay (1.87 vs 1.58 days, p < 0.0001). In the intermittent OCS cohort, rates were highest in the frequent prescribing group for GP visits (7.49 episodes; p < 0.0001 vs one-off), length of stay (2.15 days; p < 0.0001) and any prescription including OCS (25.22 prescriptions; p < 0.0001). Mean per-patient non-respiratory related and all-cause HCRU-related costs were higher with intermittent OCS than no OCS (£ 3902 vs £ 2722 and £ 8623 vs £ 4929, respectively), as were mean annualized costs (£ 565 vs £ 313 and £ 1526 vs £ 634, respectively). A dose–response relationship existed; HCRU-related costs were highest in the frequent prescribing cohort (p < 0.0001). Conclusion: Intermittent OCS use and more frequent intermittent OCS prescription patterns were associated with increased HCRU and associated costs. Improved asthma management is needed to reduce reliance on intermittent OCS in primary care. Keywords: asthma, costs, healthcare resource utilization, intermittent, oral corticosteroids Oral corticosteroids (OCS) are recommended by major treatment guidelines and recommendations, such as those from the Global Initiative for Asthma (GINA), for the management of asthma exacerbations. 1 Use of OCS, including short-term or periodic (<5 mg/day/year) for the management of asthma is associated with an increased risk of short- and long-term adverse outcomes and premature death, compared with non-use of OCS. 2–4 We previously demonstrated that this association is consistent across age, asthma severity (GINA treatment step) and prior inhaled corticosteroid (ICS) maintenance or short-acting β 2 -agonist (SABA) reliever use. 5 Our data also showed an association between one-off use of OCS and a significantly increased risk of OCS-related adverse outcomes versus non-OCS use. 5 Despite this increased risk for adverse outcomes, the limited use recommended by guidelines, and the availability of novel therapies for the chronic treatment of asthma, recent data suggest that OCS are still -Abstract Truncated-

OCS use in uncontrolled severe asthma in Canada

Oral corticosteroid stewardship: key insights from the Australasian Severe Asthma Registry

Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma

Overuse of Oral Corticosteroids, Underuse of Inhaled Corticosteroids, and Implications for Biologic Therapy in Asthma

Healthcare Resource Utilization Associated with Intermittent Oral Corticosteroid Prescribing Patterns in Asthma

Suboptimally controlled asthma in patients treated with inhaled ICS/LABA: prevalence, risk factors, and outcomes

Chronic oral corticosteroids use and persistent eosinophilia in severe asthmatics from the Belgian severe asthma registry

Systemic corticosteroids in asthma: A call to action from World Allergy Organization and Respiratory Effectiveness Group

Associations Between ICS-based Maintenance Treatment and Asthma Outcome (asthma Control, Asthma Exacerbation Hospitalization and Emergency Department Visit) in Real World: Data from CARN Study

Uncontrolled asthma: a retrospective cohort study in Japanese patients newly prescribed with medium-/high-dose ICS/LABA

The Association Between Short-Acting β2-Agonist Over-Prescription, and Patient-Reported Acquisition and Use on Asthma Control and Exacerbations: Data from Australia

Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature

Adverse impacts of corticosteroid treatment on osteoporosis/osteopenia in adult asthmatics: A retrospective ICARUS cohort study

Burden of asthma among patients adherent to ICS/LABA: A real-world study

Over-prescription of short-acting β2-agonists remains a serious health concern in Kenya: results from the SABINA III study

Overprescription of short-acting β 2 agonists: reflections from the SABINA study in Brazil

Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β2-agonist dual therapy in a primary care setting in England

Asthma: effect of excess short-acting {beta}2-agonist (SABA) inhaler prescriptions on healthcare resource utilisation

Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy

Complications of Oral Corticosteroid Use in Otolaryngology